title: Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis.
abstract: Background. There is an insufficient remyelination in the lesions of multiple sclerosis (MS). One of the factor that was found to promote remyelination is neuregulin-1 which is the ligand of ErbB4. Immune cells have been implicated in neurogenesis and oligodendrogenesis. Aims. We studied the expression of ErbB4 in the immune cells of patients with relapsing remitting (RR) multiple sclerosis (MS) and healthy controls. Methods. ErB4 expression in immune cells was studied by flow cytometry without stimulation or with stimulation with anti-CD3 and anti-CD28 monoclonal antibodies or in the presence of interferon-g or TNF-α as well as by immunoprecipitation and Western blot, and its mRNA was studied by real-time PCR. Results. We found reduced levels of ErbB4 in the total PBMCs and in T cells, monocytes, and B cells of RR MS patients. Similarly, the ErbB4 RNA levels were reduced in the immune cells of patients with RR-MS. Stimulation via CD3 and CD28 significantly upregulated the expression of ErbB4 on immune cells healthy individuals. This effect was weaker in the patients group. Conclusion. ErbB4 may play a role in the proliferation of oligodendrocyte progenitor cells, differentiation of oligodendrocytes, and remyelination, and, therefore, the reduced ErbB4 expression in immune cells of patients with RR-MS may contribute to insufficient remyelination that occurs in the disease.
authors.affiliation: Neuroimmunology laboratory, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler's Faculty of Medicine, Tel Aviv University, 64239 Tel Aviv, Israel.
authors.forename: Evgenia
authors.initials: E
authors.lastname: Tynyakov-Samra
authors.forename: Eitan
authors.initials: E
authors.lastname: Auriel
authors.forename: Yifat
authors.initials: Y
authors.lastname: Levy-Amir
authors.forename: Arnon
authors.initials: A
authors.lastname: Karni
references.citation: J Clin Invest. 2006 Dec;116(12):3252-7
references.pmid: 17099776
references.citation: J Neurosci. 2003 Sep 24;23(25):8808-19
references.pmid: 14507981
references.citation: J Immunol. 2006 Jun 15;176(12):7768-74
references.pmid: 16751425
references.citation: Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50
references.pmid: 8383326
references.citation: Exp Cell Res. 2009 Feb 15;315(4):611-8
references.pmid: 19046966
references.citation: Brain. 2006 Dec;129(Pt 12):3165-72
references.pmid: 16921173
references.citation: Neuropathol Appl Neurobiol. 2007 Jun;33(3):277-87
references.pmid: 17442065
references.citation: Cancer Res. 2001 Mar 1;61(5):2169-76
references.pmid: 11280782
references.citation: J Neuroimmunol. 2008 Mar;195(1-2):186-93
references.pmid: 18329726
references.citation: Pharmacol Ther. 2009 Jan;121(1):115-22
references.pmid: 19046988
references.citation: J Neurol Sci. 2010 Aug 15;295(1-2):31-7
references.pmid: 20541775
references.citation: J Neuroimmunol. 2003 Sep;142(1-2):10-6
references.pmid: 14512160
references.citation: J Neuroimmunol. 1999 Dec;100(1-2):233-42
references.pmid: 10695733
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Neuron. 2004 Oct 14;44(2):251-61
references.pmid: 15473965
references.citation: N Engl J Med. 2006 Mar 2;354(9):942-55
references.pmid: 16510748
references.citation: J Neuroimmunol. 2002 Apr;125(1-2):134-40
references.pmid: 11960649
references.citation: J Clin Invest. 1995 Jun;95(6):2711-9
references.pmid: 7769110
references.citation: J Immunol. 2006 Sep 15;177(6):4196-202
references.pmid: 16951385
references.citation: Ann Neurol. 1989 Feb;25(2):204-7
references.pmid: 2521994
references.citation: Nat Med. 1999 Jan;5(1):49-55
references.pmid: 9883839
references.citation: J Neuroimmunol. 2011 Mar;232(1-2):171-8
references.pmid: 21111488
references.citation: J Mol Med (Berl). 2010 Nov;88(11):1133-41
references.pmid: 20625696
references.citation: Ann Neurol. 2000 Jun;47(6):707-17
references.pmid: 10852536
references.citation: Annu Rev Neurosci. 2008;31:247-69
references.pmid: 18558855
references.citation: J Neurosci Res. 2004 May 15;76(4):453-65
references.pmid: 15114617
references.citation: Lancet. 2002 Apr 6;359(9313):1221-31
references.pmid: 11955556
references.citation: Nat Med. 2005 Sep;11(9):966-72
references.pmid: 16086023
references.citation: Glia. 2007 Apr 1;55(5):537-45
references.pmid: 17236210
references.citation: J Exp Med. 2004 Apr 5;199(7):971-9
references.pmid: 15067033
references.citation: Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):599-603
references.pmid: 9012830
references.citation: Mol Cell Neurosci. 2006 Jan;31(1):149-60
references.pmid: 16297637
references.citation: Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6873-8
references.pmid: 10359806